The Lancet Publishes: More Than 936 Million Have Obstructive Sleep Apnea Worldwide
More than 936 million people have obstructive sleep apnea – the disease’s first prevalence update in more than a decade – according to The Lancet Respiratory Medicine, the world’s leading journal in its field.
The Lancet today published a multinational analysis by ResMed (NYSE: RMD) (ASX: RMD) and 12 academic leaders in sleep research. The results were first presented at the ATS 2018 International Conference in San Diego.
This figure is nearly 10 times greater than the World Health Organization’s 2007 estimate of more than 100 million, renewing calls for physicians to step up their efforts to screen, diagnose, and prescribe treatment for those who unknowingly suffer.
“More than 85 percent of sleep apnea patients are undiagnosed, meaning hundreds of millions repeatedly suffocate instead of getting healthy, restful sleep each night,” said Carlos M. Nunez, M.D., a study coauthor and ResMed’s chief medical officer. “This raises their risk of workplace and roadway accidents, and can contribute to other significant health problems, such as hypertension, cardiovascular disease, or even poor glucose control for diabetic patients. We know the risks, and now we know the size of the problem is nearly 10 times greater than previously thought. Addressing it starts with screening patients we know to be high-risk.”
Why is sleep apnea mostly undiagnosed?
Sufferers often don’t know they’re suffering. They’ll stop breathing for 10 seconds or more throughout the night – called an “apnea” – and repeatedly wake to breathe and prevent suffocation. They rarely remember waking, but the disruptive cycle causes chronic sleep deprivation.
“Many will attribute the resulting tiredness to aging or stress,” said Nunez. “Others will mention the problem to their doctor, only to be misdiagnosed with insomnia, migraines, chronic fatigue, or other conditions. Misdiagnosis is especially common with women, since sleep apnea was long thought to be much more common in men.”
Today, women account for 40 percent of newly diagnosed sleep apnea patients.
Another reason many suffer unknowingly can be blamed on cultural ideas of what constitutes good sleep.
“For instance, some believe snoring may simply be a normal feature of how some people sleep, when in fact it’s one of the most important signs for the risk of having sleep apnea,” Nunez said. “With a global prevalence that approaches 1 billion people, patients and physicians need to consider the risks and ask the questions that may ultimately help them sleep and live better. This is no longer a problem that can be treated lightly or ignored.”
Who is at risk for sleep apnea?
More than half of all people with obesity, heart failure, stroke or transient ischemic attack (TIA), atrial fibrillation, or type 2 diabetes also have sleep apnea, according to leading research.
Snoring is the number-one indicator of sleep apnea in men and women, though not everyone who snores has it – and not everyone who has it snores.
People told they stop breathing for long periods during sleep are also at a higher risk for the disorder.
“The bottom line is: If you’re constantly tired or have other conditions linked to sleep apnea, it never hurts to ask your doctor about it,” said Nunez. “Don’t settle for being tired all the time. Sleep apnea is 100 percent treatable. You can improve your sleep, your mood, your relationships at work and home, your health, perhaps even other medical conditions you’re managing. But first, you have to find out.”
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines13.11.2019 11:29:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that NHS Wales has accepted an offer for all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England. This means that once the contract is finalized, patients with CF in Wales ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can access ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations can access SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor in the coming weeks. The agreement also offers expanded access to KALYDECO ® (ivacaftor) to include those patients ages 12 months and older who have one of the nine licensed gating mutations. “Today’s a
Software Testing and Digital Transformation Partners Recognized at 2019 Tricentis Partner Awards13.11.2019 11:00:00 CET | Press release
Tricentis, the cloud’s #1 Continuous Testing Platform, today recognized top-performing partners from around the world during Tricentis Accelerate 2019 in Vienna, Austria. In its 5th year, the Tricentis Partner Awards recognize organizations for accelerating digital transformation across the enterprise. Award winners were selected from more than 300 different partners worldwide based on their collaboration with Tricentis, customers, and their advocacy for Tricentis’ automation methodologies. “Tricentis partners are leading the way for organizations to innovate faster, reduce business risk, and optimize cost,” said Alan Ota, Senior Vice President of Strategic Alliances, Tricentis. “Our partners are instrumental to our business and are focused on delivering the best in-class testing solutions to our joint customers. Our tremendous growth would not be possible without our global partners. We’re proud to acknowledge the achievements made by our partners in 2019 and look forward to continuin
Applicaster Appoints Jason Johns as Vice President of Sales, EMEA and APAC13.11.2019 10:00:00 CET | Press release
Applicaster, the company simplifying the lifecycle management of direct-to-consumer media applications, today announced the appointment of Jason Johns as Vice President of Sales, EMEA and APAC. In his role, Johns will oversee Applicaster’s EMEA and APAC commercial and go-to-market strategies. “There is an incredible amount of opportunity in the media app market,” said Johns. “Because of our ability to enable frictionless growth for customers, we’re very well positioned to take advantage of this opportunity. Beyond the market opportunity, I was attracted to Applicaster because of the company’s customer-first culture plus its ability and desire to drive value lead engagements. Few businesses buy technology without a clear understanding of the business case and full transparency of the cost-of-ownership around their technology investments - Applicaster understands this and provides flexible commercial models that scale and can easily be upgraded and expanded as business requirements evolv
Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy13.11.2019 09:00:00 CET | Press release
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Rucaparib will soon be available as an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.3 Rucaparib is indicated for eligible patients regardless of BRCA status, which means it can be prescribed for women who harbor a BRCA mutation or who are BRCA wild-type.3 “We very much welcome the arrival of the PARP inhibitor rucaparib, which offers a new treatment option after surgery and two lines of chemotherapy to all eligible women affected by relapsed ovarian cancer,” declared Nicoletta Cerana, National President of Acto Onlus, the number one Italian network of patient associations involved in the fight against ovarian cancer and gynecological tumors. “Ovarian cancer is a highly lethal
Traxens Presents Solutions for Port Industry at Smart Ports Barcelona13.11.2019 07:30:00 CET | Press release
Traxens, a company providing high-value data and services for the supply chain industry, announces today that it will present its smart asset tracking solutions at the Smart Ports Barcelona event, Smart Ports, Piers of the Future, November 19 to 21. Its tailored Industrial Internet of Things (IIoT) solutions are specifically designed to meet the needs of the port industry by providing near real-time insight into the end-to-end global supply chain. Traxens’ solution provides comprehensive, precise and timely data on cargo, through tracking logistic assets in transit anywhere in the world. Traxens’ patented breakthrough Internet of Things (IoT) technology brings improved efficiency and security, greater transparency and enhanced asset utilization whilst opening up new opportunities for all actors involved in the global supply chain. With Traxens’ solutions, ports can improve their efficiency and the interoperability of the systems with a trusted third party. For example, the Cargo Commun
PMC Group Announces Agreement to Acquire Lanxess’ Organotin Specialties Business13.11.2019 06:30:00 CET | Press release
PMC Group N.A., Inc. ("PMC") and Lanxess Organometallics GmbH are pleased to announce that the parties have reached an agreement whereby PMC’s European subsidiary will acquire the organotin specialties product line (the “Business”) from Lanxess. The transaction is scheduled to close by year end, subject to customary closing conditions. The Business includes Lanxess’ global organotin catalyst, organotin specialties and intermediates product lines. The transaction includes a toll manufacturing agreement under which Lanxess will continue to manufacture certain products post-closing for PMC at its Bergkamen, Germany organometallics manufacturing facility. Mr. Debtosh Chakrabarti, President of PMC said, “This acquisition represents PMC’s continuing commitment to the organotin industry and is synergistic to our existing organometallics and catalyst businesses. We believe that the customer base of the Business as well as all of PMC’s customers will benefit significantly from combining the tec